Cystadenomas of the Pancreas

Abstract

This experience suggests that enucleation of mucinous cystadenomas of the pancreas can be performed safely and that the recurrence rate is low after this procedure. The authors conclude that enucleation is an adequate procedure for benign cystic neoplasms of the pancreas.

Pancreatic mucinous cystoadenomas and cystoadenocarcinomas: differential diagnosis by means of MRI

“…[7][8][9][10][11][12] In fact, the 5-year survival rate of benign MCNs has been demonstrated to be 100%, with no local recurrence at 57-month follow-up vs 57% for malignant MCNs; 7 5-year survival rate appears worse for invasive forms (,20%), similar to that of ductal pancreatic adenocarcinoma. 13 This is the reason why some authors have proposed the so-called "parenchyma-sparing" surgical procedures for benign forms such as distal pancreatectomy without splenectomy, 7,12,14,15 middle pancreatectomy 8,16 or enucleation.…”

“…13 This is the reason why some authors have proposed the so-called "parenchyma-sparing" surgical procedures for benign forms such as distal pancreatectomy without splenectomy, 7,12,14,15 middle pancreatectomy 8,16 or enucleation. 8,10 These more conservative approaches have demonstrated the ability to reduce the risk of endocrine and/or exocrine pancreatic insufficiency and to preserve the spleen. In our study, the most accurate sign of malignancy (accuracy of 96.9%) was the depiction of mural nodules (Figure 2b), which was seen in 20 of 22 (91%) MCACs and in none (0%) of the 43 MCAs.…”

“…2 Recent studies have demonstrated some differences in terms of prognosis and therapy between benign and malignant forms of MCNs. [7][8][9][10][11][12] Concerning prognosis, it has been demonstrated that benign forms have a 5-year survival rate of 100%, with no local recurrence at 57-month follow-up, while malignant forms have a 5-year survival rate of 57%, 7 similar to that of malignant forms of intraductal papillary mucinous neoplasms. Furthermore, the 5-year survival rate of invasive forms of MCNs is ,20%, similar to that of ductal adenocarcinoma of the pancreas.…”

“…Furthermore, the 5-year survival rate of invasive forms of MCNs is ,20%, similar to that of ductal adenocarcinoma of the pancreas. 13 Concerning therapy, "parenchyma-sparing" surgical procedures such as distal pancreatectomy without splenectomy, 7,12,14,15 middle pancreatectomy 8,16 or enucleation 8,10 have been suggested to reduce the risk of post-operative endocrine and/or exocrine pancreatic insufficiency and to preserve the spleen. [7][8][9][10] For benign MCNs ,3 cm in size and without mural nodules, clinical radiological follow-up has been suggested.…”

“…13 Concerning therapy, "parenchyma-sparing" surgical procedures such as distal pancreatectomy without splenectomy, 7,12,14,15 middle pancreatectomy 8,16 or enucleation 8,10 have been suggested to reduce the risk of post-operative endocrine and/or exocrine pancreatic insufficiency and to preserve the spleen. [7][8][9][10] For benign MCNs ,3 cm in size and without mural nodules, clinical radiological follow-up has been suggested. 8,[17][18][19] Nowadays, there are only a few published studies to distinguish benign forms of MCNs from malignant forms of MCNs based on CT. 9,20 Furthermore, in a recently published study, Theruvath et al 21 proved the lower effectiveness of CT compared with MRI in predicting the diagnosis of MCNs, but at present there are no published studies based on MRI to distinguish benign forms of MCNs from malignant forms of MCNs.…”